Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Condition: HER2-positive Recurrent / Metastatic Breast Cancer Interventions: Drug: pyrotinib tablet; Drug: Montmorillonite Power; Drug: Loperamide Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)
Conditions: Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive Interventions: Drug: Neratinib; Drug: Loperamide; Drug: Colesevelam Sponsors: Spanish Breast Cancer Research Group; Puma Biotechnology, Inc.; Pierre Fabre Laboratories Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Condition: HER2-positive Recurrent / Metastatic Breast Cancer Interventions: Drug: pyrotinib tablet; Drug: Montmorillonite Power; Drug: Loperamide Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)
Conditions: Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive Interventions: Drug: Neratinib; Drug: Loperamide; Drug: Colesevelam Sponsors: Spanish Breast Cancer Research Group; Puma Biotechnology, Inc.; Pierre Fabre Laboratories Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Condition: HER2-positive Recurrent / Metastatic Breast Cancer Interventions: Drug: pyrotinib tablet; Drug: Montmorillonite Power; Drug: Loperamide Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)
Conditions: Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive Interventions: Drug: Neratinib; Drug: Loperamide; Drug: Colesevelam Sponsors: Spanish Breast Cancer Research Group; Puma Biotechnology, Inc.; Pierre Fabre Laboratories Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Condition: HER2-positive Recurrent / Metastatic Breast Cancer Interventions: Drug: pyrotinib tablet; Drug: Montmorillonite Power; Drug: Loperamide Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)
Conditions: Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive Interventions: Drug: Neratinib; Drug: Loperamide; Drug: Colesevelam Sponsors: Spanish Breast Cancer Research Group; Puma Biotechnology, Inc.; Pierre Fabre Laboratories Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
Condition: HER2-positive Recurrent / Metastatic Breast Cancer Interventions: Drug: pyrotinib tablet; Drug: Montmorillonite Power; Drug: Loperamide Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
